Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(4.56)
# 252
Out of 5,148 analysts
126
Total ratings
53.04%
Success rate
28.82%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMUX Immunic | Maintains: Buy | $8 → $5 | $1.06 | +371.70% | 8 | Mar 2, 2026 | |
| FBLG FibroBiologics | Maintains: Buy | $5 → $4 | $0.42 | +853.52% | 9 | Feb 26, 2026 | |
| ARDX Ardelyx | Maintains: Buy | $10 → $18 | $6.47 | +178.21% | 2 | Feb 20, 2026 | |
| ZBIO Zenas BioPharma | Reiterates: Buy | $44 | $25.56 | +72.14% | 6 | Feb 10, 2026 | |
| KOD Kodiak Sciences | Reiterates: Buy | $38 | $27.36 | +38.89% | 9 | Feb 10, 2026 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $6 | $1.26 | +376.19% | 4 | Feb 6, 2026 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $52 → $56 | $29.32 | +91.00% | 13 | Nov 12, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $20 → $26 | $11.46 | +126.88% | 11 | Oct 31, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $72 → $88 | $77.43 | +13.65% | 2 | Oct 20, 2025 | |
| DMAC DiaMedica Therapeutics | Reiterates: Buy | $12 | $7.78 | +54.24% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $16 | $1.19 | +1,244.54% | 9 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $56 | $13.68 | +309.36% | 7 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $4.33 | +84.76% | 4 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $5.62 | +77.94% | 13 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $28.60 | +11.89% | 3 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $9.33 | +285.85% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $581.37 | -95.18% | 1 | Aug 22, 2023 |
Immunic
Mar 2, 2026
Maintains: Buy
Price Target: $8 → $5
Current: $1.06
Upside: +371.70%
FibroBiologics
Feb 26, 2026
Maintains: Buy
Price Target: $5 → $4
Current: $0.42
Upside: +853.52%
Ardelyx
Feb 20, 2026
Maintains: Buy
Price Target: $10 → $18
Current: $6.47
Upside: +178.21%
Zenas BioPharma
Feb 10, 2026
Reiterates: Buy
Price Target: $44
Current: $25.56
Upside: +72.14%
Kodiak Sciences
Feb 10, 2026
Reiterates: Buy
Price Target: $38
Current: $27.36
Upside: +38.89%
Akebia Therapeutics
Feb 6, 2026
Reiterates: Buy
Price Target: $6
Current: $1.26
Upside: +376.19%
Mineralys Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $52 → $56
Current: $29.32
Upside: +91.00%
Phathom Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $20 → $26
Current: $11.46
Upside: +126.88%
Tarsus Pharmaceuticals
Oct 20, 2025
Maintains: Buy
Price Target: $72 → $88
Current: $77.43
Upside: +13.65%
DiaMedica Therapeutics
Aug 15, 2025
Reiterates: Buy
Price Target: $12
Current: $7.78
Upside: +54.24%
Aug 14, 2025
Reiterates: Neutral
Price Target: $16
Current: $1.19
Upside: +1,244.54%
Aug 1, 2025
Maintains: Buy
Price Target: $48 → $56
Current: $13.68
Upside: +309.36%
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $4.33
Upside: +84.76%
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $5.62
Upside: +77.94%
May 12, 2025
Reiterates: Buy
Price Target: $32
Current: $28.60
Upside: +11.89%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $9.33
Upside: +285.85%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $581.37
Upside: -95.18%